International Journal of Cancer · 2020 · 57 citations · 35 references
MedicineImmunologyOncologyCancer ImmunologyTumor ImmunologyTumor MicroenvironmentCancer ImmunotherapyCancer Survival AnalysisImmuno-oncology BiomarkersMolecular Tumor ProfilingTumor Immune MicroenvironmentTumor ImmunopathologyBreast Cancer PrognosisCd4 Positive T CellsCox RegressionImmune Biomarkers In CancerPredictive Biomarker DiscoveryPredictive Biomarker ModelingPrognostic ClassificationPrognostic Indices
Our study aims to construct a prognosis-related immune phenotype classifier for predicting clinical prognosis and immune activity in triple-negative breast cancer (TNBC). A total of 237 patients with TNBC from Sun Yat-sen University Cancer Center (SYSUCC) and 533 patients with TNBC from public datasets were included in our study. A stromal immune quantified index was generated with a LASSO Cox regression model based on five prognosis-related immune cells evaluated by CIBERSORT or IHC and was used to determine immune phenotypes. Immune features were evaluated in the samples before chemotherapy. A total of 119 patients in the SYSUCC training cohort were classified into immune Phenotypes A and B according to the density of stromal CD4+ T cells, γδ T cells, monocytes, M1 macrophages and M2 macrophages. Phenotype A predicted better survival than Phenotype B, and the classification was further validated in the testing cohort of 118 patients and the validation cohort of 533 patients. In the combined cohort, significant differences were found in Phenotype A compared to Phenotype B for the 5-year overall survival (83.5% vs 65.8%, respectively, P < .01) and the 5-year disease-free survival (87.3% vs 76.0%, respectively, P < .01). In Phenotype A, immune-related pathways were significantly enriched, and a higher level of immune checkpoint molecules, including PD-L1, PD-1 and CTLA-4, could be observed. The immune phenotype classification was an independent prognostic indicator for TNBC and might serve as a potential predictor for immune activity within the tumor microenvironment.
35
Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2019 · 21K citations · Full text
Robust enumeration of cell subsets from tissue expression profiles
Aaron M. Newman, Chih Long Liu, Michael R. Green et al. · Nature Methods · 2015 · 14.1K citations · Full text
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
Christina Curtis, Sohrab P. Shah, Suet‐Feung Chin et al. · Nature · 2012 · 6.4K citations · Full text
Life Sciences, Genetics, Oncology +14